PHARMACOLOGY OF COGNITION IN SCHIZOTYPAL PERSONALITY

描述（改编自申请人摘要）：拟定研究目的 定义与SPD相关的认知障碍，并评估 安非他明急性药物干预对 SPD患者的认知功能。 SPD患者分享重要的 慢性前列腺炎的现象学、遗传学和神经生物学共性 精神分裂症，特别是核心认知/注意力障碍。 他们的 然而，这项研究最大限度地减少了与 精神分裂症患者的研究，并提供了一个机会， 解开多重病理生理机制牵连在 精神分裂症 像精神分裂症患者一样，SPD患者表现出受损的表现， 在视觉空间工作记忆、语言学习和持续性 与其他人格障碍患者和正常人相比， 迄今为止，研究者的研究中的控制。 初步数据提示 安非他明可以改善SPD患者的这些认知障碍。 本研究旨在验证SPD患者将 在语言和视觉空间领域都表现出认知障碍 分别在三个方面的认知功能相比，其他非奇 群集性人格障碍（OPD）患者和正常对照组：1）工作 记忆（起搏听觉序列加法测试（PASAT）和DOT测试）2） 学习和记忆（连续词表学习和韦氏记忆量表 视觉再现（WMS-VR））和3）持续注意力（连续 性能任务（CPT-IP），数字和形状。 SPD患者将 在安慰剂和安非他明测试期间对这些认知任务进行评估 假设4）他们将证明显着改善， 在这三个领域的表现后，管理30毫克。 口腔 安非他明和5）将有一个显着的诊断药物相互作用 对于SPD组的这些认知任务的表现， 与OPD或OPD相比，表现出显着改善的性能 正常对照组服用安非他明后与安慰剂比较。

DESCRIPTION (Adapted from applicant's abstract): The proposed studies aim to define the cognitive impairment associated with SPD and to evaluate the effect of an acute pharmacologic intervention with amphetamine on the cognitive function of SPD patients. SPD patients share important phenomenologic, genetic, and neurobiologic commonalities with chronic schizophrenia, particularly a core cognitive/attentional impairment. Their study, however, minimized the multiple confounding artifacts associated with the study of schizophrenic patients and offers an opportunity to potentially disentangle the multiple pathophysiologic mechanisms implicated in the schizophrenic disorders. Like schizophrenic patients, SPD patients demonstrate impaired performance on tests of visuospatial working memory, verbal learning, and sustained attention compared to other personality disorder patients and normal controls in the investigator's studies to date. Preliminary data suggests amphetamine can ameliorate these cognitive impairments in SPD patients. This study is designed to test the primary hypotheses that SPD patients will show cognitive impairment in both verbal and visuospatial domains respectively in three areas of cognitive function compared to other non-odd cluster personality disorder (OPD) patients and normal controls: 1) working memory (Paced Auditory Serial Addition Test (PASAT) and DOT tests) 2) learning and memory (serial word list learning and Wechsler Memory Scale Visual Reproduction (WMS-VR)) and 3) sustained attention (Continuous Performance Task (CPT-IP), digits and shapes. SPD patients will be evaluated on these cognitive tasks during placebo and amphetamine to test the hypothesis that 4) they will demonstrate significant improvement in performance in these three domains after administration of 30 mgs. of oral amphetamine and 5) there will be a significant diagnosis by drug interaction for the performance of these cognitive tasks with the SPD group demonstrating significantly improved performance compared to the OPD or the normal comparison group after amphetamine compared to placebo.